Tisdag 13 Maj | 19:25:24 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-10-22 07:50 Kvartalsrapport 2025-Q3
2025-07-18 07:50 Kvartalsrapport 2025-Q2
2025-04-30 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2025-04-29 - Årsstämma
2025-04-29 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-08-15 - Kvartalsrapport 2024-Q2
2024-05-23 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2024-05-22 - Årsstämma
2024-05-02 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-06-02 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2023-06-02 - Årsstämma
2023-05-04 - Kvartalsrapport 2023-Q1
2023-03-24 - Extra Bolagsstämma 2023
2023-03-08 - Bokslutskommuniké 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-10-03 - Extra Bolagsstämma 2022
2022-08-24 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2022-06-02 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-03-09 - Bokslutskommuniké 2021
2021-11-26 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Vimian Group är en koncern verksamma inom djurhälsa. Bolaget levererar via sina dotterbolag läkemedel och tekniska lösningar till veterinärer, laboratorier och husdjursägare. Produkterna inkluderar exempelvis läkemedel med tillhörande klinisk forskning samt digitala plattformar för veterinärkliniker. Bolaget är verksamma på en global nivå med huvudkontor i Stockholm.
2025-04-29 07:45:00

Strong earnings growth and Main Market uplift

  • Net revenue increased by 18 per cent to EUR 107.5m (91.3) with organic growth of 4 per cent
  • Adjusted EBITA increased 18 per cent to EUR 28.3m (24.1) corresponding to a margin of 26.3 per cent (26.3)
  • Operating profit (EBIT) of EUR 15.6m (13.4)
  • Net result of EUR 4.7m (3.7) and earnings per share before and after dilution EUR 0.01 (0.01)
  • Cash flow from operating activities of EUR 17.1 (11.2)

“We delivered a strong adjusted EBITA growth of 18 per cent, reaching EUR 28.3 million for the first quarter. Organic revenue growth in the quarter reached 4 per cent, as previously communicated negatively impacted by the final adjustment of the former annual ordering program in our MedTech segment’s orthopedics business in the US. The remaining three operating segments delivered double-digit organic growth in the quarter”, says Patrik Eriksson, CEO Vimian Group and continues:

We ended the quarter with our first day of trading as a Large Cap company at Nasdaq Stockholm Main Market. This was an important milestone for Vimian as a public company, to further improve liquidity in the share and strengthen access to the international capital markets.”

A telephone and webcast will be held for investors, analysts, and media, today at 09.00 (CET). The conference will be held in English and include a question-and-answer session.

To attend the telephone conference:
Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
https://conference.inderes.com/teleconference/?id=5008510

To attend the webcast:
Link: https://vimian-group.events.inderes.com/q1-report-2025

Related presentation materials will be available on Vimian’s website (https://vimian.com/investors/reports-and-presentations/) ahead of the telephone and web conference.